BRAF and cutaneous melanoma: We note that the first published case of a patient with a BRAF-mutated metastatic conjunctival melanoma treated with vemurafenib was reported  7 years after the first clinical results of this drug17, and 5 years after FDA approval for cutaneous melanoma patients18.